{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-23-016076","form_type":"8-K","ticker":"AYTU","cik":"0001385818","company_name":"AYTU BIOPHARMA, INC","filed_at":"2023-09-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.758409+00:00","generated_at":"2026-06-10T08:05:40.308719+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Aytu Q4 record revenue $30.7M, positive Adj. EBITDA $7.7M, prescriptions up 32%","bullets":["Q4 net revenue $30.7M (+12% YoY); Rx segment $23.3M (+24%); total prescriptions 155,562 (+32%).","Net loss improved to $2.5M ($0.59/share) from $16.1M ($8.95/share) a year ago; $0.6M net income excluding impairment.","Adjusted EBITDA positive $7.7M in Q4 vs negative $3.9M; FY23 Adj. EBITDA positive $3.2M vs negative $21.5M.","Cash ended at $23.0M, up from $19.2M in March; company plans to monetize or discontinue Consumer Health segment.","Gross margin improved to 60% (Q4) and 62% (FY) from 54% in both prior-year periods."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-23-016076","json":"https://secwatch.observer/filing/0001558370-23-016076.json","markdown":"https://secwatch.observer/filing/0001558370-23-016076.md","text":"https://secwatch.observer/filing/0001558370-23-016076.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1385818/000155837023016076/0001558370-23-016076-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1385818/000155837023016076/aytu-20230927x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T08:05:40.308719+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2ff1547bd7828df8fc55cb2a511d97f4909f20d4","claim":"AYTU BIOPHARMA, INC reported the fiscal quarter ended June 30, 2023 results: revenue $30.7 million, net income $2.5 million, EPS $0.59 per share.","evidence_excerpt":"BioPharma Reports Record Revenues, Record Prescriptions, and Highest Adjusted EBITDA in Company History for the Fourth Quarter of Fiscal Year 2023 Q4 2023 net revenue of $30.7 million; Adjusted EBITDA of $7.7 million Record Q4 2023 total prescriptions increased 32% compared to Q4 2022 Rx Segment net revenue of $23.3 million and Adjusted EBITDA of $8.3 million","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1385818/000155837023016076/0001558370-23-016076-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fiscal quarter ended June 30, 2023"},{"label":"Revenue","value":"$30.7 million"},{"label":"Net income","value":"$2.5 million"},{"label":"EPS","value":"$0.59 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"f07600aeee8dd8a6cb96152b062ad788d09b6b32","claim":"AYTU BIOPHARMA, INC reported the fiscal year ended June 30, 2023 results: revenue $107.4 million, net income $17.1 million, EPS $5.11 per share.","evidence_excerpt":"were $23.0 million at June 30, 2023 compared to $19.2 million at March 31, 2023. ​ FY 2023 Commercial Highlights (12 months ending June 30, 2023) ● Total net revenue was $107.4 million, an increase of 11% from $96.7 million in net revenue in FY 2022. ● Net revenue from the Company’s Rx segment was $73.8 million during FY 2023 compared to $61.1 million in FY","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1385818/000155837023016076/0001558370-23-016076-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fiscal year ended June 30, 2023"},{"label":"Revenue","value":"$107.4 million"},{"label":"Net income","value":"$17.1 million"},{"label":"EPS","value":"$5.11 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}